Japan's NEC Expands Biopharma Presence With AI-Based R&D

Now in Norway, Netherlands and Germany

14 Apr 2023

Japanese tech major re-structures its teams for artificial intelligence-based drug development and strategies while expanding its presence in Europe. With confidence in the utility of AI for discovery, it is retaining a key focus on oncology while adding infectious diseases to its targets.

NEC has expanded its biopharmaceutical presence in Europe — NEC has expanded its biopharma presence in Europe from Norway to the Netherlands and Germany • Source: Shutterstock

Major Japanese technology firm NEC Corporation has expanded its presence in the pharmaceutical industry in Europe, establishing two additional operations in the biopharmaceutical sector at the end of March. NEC Bio B.V. (NB) in Hilversum, the Netherlands and NEC Bio Therapeutics (NBT) in Mannheim, Germany have joined its other healthcare tech-related subsidiaries.

Although it has been providing pharma firms with its artificial intelligence (AI) and ICT (information and communications technology) systems and...